The 20 mg/mL dose of MS treatment Copaxone® (glatiramer acetate) will be deleted from listing on the Pharmaceutical Benefits Scheme (PBS) from 1 July 2019.
The request for this deletion was made by the sponsor, Teva Pharma Australia Pty Ltd. Teva have stated that, “since the launch of Copaxone® 40 mg three times a week in 2015, there has been a shift towards this formulation for MS patients in Australia. Copaxone® 40 mg three times a week demonstrated comparable efficacy to Copaxone® 20 mg daily, with 60% fewer injections and a 50% reduction in injection-related adverse events. 1-3”
The 40 mg/mL dose is still available and listed on the PBS.
Teva offer all people being treated with Copaxone® access to a Care Xone patient support program by calling 1800 502 802 or emailing firstname.lastname@example.org
Please discuss with your neurologist whether Copaxone® (glatiramer acetate) is the right treatment for you, and if the deletion of the 20 mg/mL dose has implications for your treatment plan.
For more information about Copaxone® (glatiramer acetate), please visit:
For details of the criteria you need to meet to obtain Copaxone® (glatiramer acetate) through the PBS, please visit the PBS web-site:
To see the official advice on the PBS web-site regarding this deletion, please visit:
References: 1. COPAXONE Approved Product Information, 15 May 2018. 2. Wolinsky JS, et al. Multi Scler Relat Disord 2015;4:370-6. 3. Comi G, et al. Ann Neurol 2011,69:75-82.